Evidence map›Paper›PMID 26425036›Full record

SynthesisJournal of Korean medical science2015

Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis.

Gaeun Kim, Young Woo Eom, Soon Koo Baik, Yeonghee Shin, Yoo Li Lim, Moon Young Kim, Sang Ok Kwon, Sei Jin Chang

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of Korean medical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 8 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 8 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Locoregional delivery of stem cell-based therapies.Science translational medicine · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gaeun KimResearch Institute for Nursing Science, Keimyung University, College of Nursing, Daegu, Korea.
Young Woo EomCell Therapy and Tissue Engineering Center, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Soon Koo BaikCell Therapy and Tissue Engineering Center, Yonsei University, Wonju College of Medicine, Wonju, Korea. ; Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Yeonghee ShinResearch Institute for Nursing Science, Keimyung University, College of Nursing, Daegu, Korea.
Yoo Li LimDepartment of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Moon Young KimDepartment of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Sang Ok KwonDepartment of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Sei Jin ChangInstitute of Occupation and Environmental Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea.
Yonsei University · KRKeimyung University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.

Indexed as

Cell- and Tissue-Based TherapyCell DifferentiationHepatocytesHumansLiverLiver DiseasesLiver Function TestsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationChronic Liver DiseasesMesenchymal Stem CellsMeta-analysisSystematic Review

Identifiers

PMID26425036
PMCPMC4575928
OpenAlexW2156119394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.